For mid-size and specialty CROs
Win the bid on AI-native capability.
Axiom is an AI-native clinical monitoring layer you can bundle into your service offering. Compete with IQVIA and ICON on technical capability without the engineering investment. Run more trials with the same CRA headcount.
How this partnership works.
Improve bid win rate, margin, and brand control.
Win bids you're losing today.
Large CROs now pitch AI-native monitoring in most Phase 2/3 proposals. Bundling Axiom lets you match that capability without an 18-month internal build.
Convert labor hours to software margin.
Axiom replaces ~50% of routine SDV labor, ~70% of MVR drafting, and ~60% of DM query labor. Reinvest those hours in higher-value CRA work, or convert them into margin.
White-label deployment.
Axiom runs under your brand, so sponsors see your monitoring capability, not ours. Multi-sponsor isolation is built in, and your portfolio stays yours.
Who we partner with
Mid-size and specialty CROs running 20+ concurrent Phase 2/3 trials.
Therapeutic focus in oncology, neurology, immunology, or rare disease.
Demonstrated appetite for AI-native capability as a competitive lever.
Willingness to co-invest in a 90-day pilot on one live study.
Who we do not partner with
CROs whose primary differentiator is low-cost labor (our economics compress yours, not expand).
CROs unwilling to share proposal-stage pipeline with Axiom (we can't help you win bids we don't know you're submitting).